These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30268633)

  • 1. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
    Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
    Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    Angeli D; Salvi S; Tedaldi G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre.
    Evans DG; Green K; Burghel GJ; Forde C; Lalloo F; Schlecht H; Woodward ER
    Fam Cancer; 2024 Jun; 23(2):187-195. PubMed ID: 38478259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of panel testing in familial breast and ovarian cancer.
    Prapa M; Solomons J; Tischkowitz M
    Clin Med (Lond); 2017 Dec; 17(6):568-572. PubMed ID: 29196360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
    PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
    Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
    J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
    Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
    Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
    J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network.
    Fan X; Wynn J; Shang N; Liu C; Fedotov A; Hallquist MLG; Buchanan AH; Williams MS; Smith ME; Hoell C; Rasmussen-Torvik LJ; Peterson JF; Wiesner GL; Murad AM; Jarvik GP; Gordon AS; Rosenthal EA; Stanaway IB; Crosslin DR; Larson EB; Leppig KA; Henrikson NB; Williams JL; Li R; Hebbring S; Weng C; Shen Y; Crew KD; Chung WK
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34377931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.
    Lerner-Ellis J; Mighton C; Lazaro C; Watkins N; Di Gioacchino V; Wong A; Chang MC; Charames GS
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):871-879. PubMed ID: 32885271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).
    Fernández Madrigal L; Rodríguez Garcés MY; Jiménez Ruiz FJ
    Curr Probl Cancer; 2023 Dec; 47(6):101008. PubMed ID: 37704491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Population-Based Study of Genes Previously Implicated in Breast Cancer.
    Hu C; Hart SN; Gnanaolivu R; Huang H; Lee KY; Na J; Gao C; Lilyquist J; Yadav S; Boddicker NJ; Samara R; Klebba J; Ambrosone CB; Anton-Culver H; Auer P; Bandera EV; Bernstein L; Bertrand KA; Burnside ES; Carter BD; Eliassen H; Gapstur SM; Gaudet M; Haiman C; Hodge JM; Hunter DJ; Jacobs EJ; John EM; Kooperberg C; Kurian AW; Le Marchand L; Lindstroem S; Lindstrom T; Ma H; Neuhausen S; Newcomb PA; O'Brien KM; Olson JE; Ong IM; Pal T; Palmer JR; Patel AV; Reid S; Rosenberg L; Sandler DP; Scott C; Tamimi R; Taylor JA; Trentham-Dietz A; Vachon CM; Weinberg C; Yao S; Ziogas A; Weitzel JN; Goldgar DE; Domchek SM; Nathanson KL; Kraft P; Polley EC; Couch FJ
    N Engl J Med; 2021 Feb; 384(5):440-451. PubMed ID: 33471974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery.
    Irelli A; Patruno LV; Chiatamone Ranieri S; Di Giacomo D; Malatesta S; Alesse E; Tessitore A; Cannita K
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
    Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
    Mutat Res; 2023; 827():111831. PubMed ID: 37453313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.
    Piombino C; Cortesi L; Lambertini M; Punie K; Grandi G; Toss A
    J Oncol; 2020; 2020():6384190. PubMed ID: 32733558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
    Toh M; Ngeow J
    Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer.
    Castillo-Guardiola V; Sarabia-Meseguer MD; Marín-Vera M; Sánchez-Bermúdez AI; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Cancer Genet; 2018 Dec; 228-229():1-4. PubMed ID: 30553462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer as a sentinel for hereditary cancer predisposition.
    Young EL; Thompson BA; Neklason DW; Firpo MA; Werner T; Bell R; Berger J; Fraser A; Gammon A; Koptiuch C; Kohlmann WK; Neumayer L; Goldgar DE; Mulvihill SJ; Cannon-Albright LA; Tavtigian SV
    BMC Cancer; 2018 Jun; 18(1):697. PubMed ID: 29945567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.
    Landrith T; Li B; Cass AA; Conner BR; LaDuca H; McKenna DB; Maxwell KN; Domchek S; Morman NA; Heinlen C; Wham D; Koptiuch C; Vagher J; Rivera R; Bunnell A; Patel G; Geurts JL; Depas MM; Gaonkar S; Pirzadeh-Miller S; Krukenberg R; Seidel M; Pilarski R; Farmer M; Pyrtel K; Milliron K; Lee J; Hoodfar E; Nathan D; Ganzak AC; Wu S; Vuong H; Xu D; Arulmoli A; Parra M; Hoang L; Molparia B; Fennessy M; Fox S; Charpentier S; Burdette J; Pesaran T; Profato J; Smith B; Haynes G; Dalton E; Crandall JR; Baxter R; Lu HM; Tippin-Davis B; Elliott A; Chao E; Karam R
    NPJ Precis Oncol; 2020; 4():4. PubMed ID: 32133419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.